A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)

Inclusion Criteria:

• Has locally advanced or metastatic RCC with predominantly clear cell subtype

• Has at least one measurable lesion as defined by RECIST version 1.1

• Eastern Cooperative Oncology Group (ECOG) performance status of 0-1

• Has adequate organ function defined as follows:

• Absolute neutrophil count ≥ 1,000/µL, hemoglobin level ≥ 10 g/dL and plateletcount ≥ 100,000/µL without transfusion or growth factor support within 2 weeksprior to obtaining the hematology values at screening;

• Serum creatinine level ≤ 2.0 × upper limit of normal (ULN)

• Transaminase levels (AST/ALT) ≤ 3.0 × upper limit of normal (ULN); totalbilirubin (TBILI) ≤ 1.5 mg/dL in the absence of Gilbert's disease *Cohort 1:Participants must not have received prior systemic therapy for advanced ormetastatic ccRCC

• Cohort 2: Participants must have received prior immunotherapy and no more than twoprior treatments for advanced or metastatic ccRCC

Exclusion Criteria:

• Has received prior treatment with belzutifan or other HIF2α inhibitors

• Has received prior treatment with cabozantinib

• Has had radiation therapy for bone metastases within two weeks of starting studydrug

• Has a history of untreated brain metastases or history of leptomeningeal disease orspinal cord compression

• Has failed to recover from the reversible effects of prior anticancer therapy

• Has uncontrolled or poorly controlled hypertension

• Is receiving anticoagulant therapy

• Has had any major cardiovascular event within 6 months prior to study drugadministration

• Has any other clinically significant cardiac, respiratory, or other medical orpsychiatric condition that might interfere with participation in the trial orinterfere with the interpretation of trial results

• Has had major surgery within 3 months before first study drug administration

• Has an active infection requiring systemic treatment

• Is participating in another therapeutic clinical trial